M9101
M9101 is a selective Aurora A PROTAC degrader with a DC50 of 2.3 nM. M9101 induces G2/M arrest in triple-negative breast cancer cells and potently inhibits the proliferation of multiple tumor cell lines. M9101 can be used in the research of various cancers including triple-negative breast cancer.
(Pink: Aurora A Target protein ligand; Blue: Cereblon ligand (HY-W248665); Black: linker).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C38H38ClN9O6S
- 分子量:784.28
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
[1]|
Aurora A 2.3 nM (DC50) |
Aurora B > 1 μM (DC50) |
Cereblon |
体外実験
M9101 (0.01-1000 nM; 4 h) induces selective, dose-dependent degradation of Aurora A in BT549 and BT20 triple-negative breast cancer cells[1].
M9101 (10-100 nM; 4 h) exhibits high selectivity for Aurora A in MDA-MB-231 cells, with significant degradation of only Aurora A observed in a global proteomic analysis of 4680 proteins, and no degradation of known TP0903 off-target kinases[1].
M9101 (graded concentrations; 72 h) potently inhibits the proliferation of multiple cancer cell lines, with IC50 values ranging from 11.7 nM to 80.1 nM across tested models including triple-negative breast cancer, non-small cell lung cancer, prostate cancer, melanoma, multiple myeloma, bladder cancer, lymphoma, and rhabdomyosarcoma[1].
M9101 (indicated concentrations; 12 h) induces dose-dependent G2/M phase accumulation in MDA-MB-231 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BT549 and BT20 triple-negative breast cancer cells
-
Concentration:0.01, 0.1, 0.3, 1, 3, 10, 30, 100, 300 and 1000 nM
-
Incubation Time:4 h
-
Result:Induced selective, dose-dependent degradation of Aurora A in both BT549 and BT20 cells.
Caused no significant degradation of Aurora B across the tested concentrations.
-
Cell Line:MDA-MB-231 triple-negative breast cancer cells
-
Concentration:10 and 100 nM
-
Incubation Time:12 h
-
Result:Induced dose-dependent accumulation of cells in the G2/M phase, a phenotype more pronounced than that caused by the catalytic inhibitor alisertib.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CB17/SCID (female, 6 to 8 weeks old, subcutaneous xenograft model)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.p.; daily; 5 consecutive days
-
Result:Induced 86.9% maximum degradation of Aurora A and 59.8% maximum degradation of Aurora B in tumor tissue at 10 mg/kg.
Induced 94.2% maximum degradation of Aurora A and 62.1% maximum degradation of Aurora B in tumor tissue at 20 mg/kg.
Caused no obvious changes in body weight with either dose.
化学情報
-
分子量 784.28
-
分子式 C38H38ClN9O6S
-
SMILES
O=C1NC(CCC1N2C(C3=CC4=C(C=C3C2=O)CN(C4)C5CCN(CC5)C6=CC=C(NC7=NC=C(Cl)C(NC8=CC=CC=C8S(N(C)C)(=O)=O)=N7)C=C6)=O)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)